Mittie K. Doyle

4.8k citations

41 papers · 3.1k indexed · 3 hit papers · h-index 24

Co-authors: Mahboob U. Rahman Elizabeth C. Hsia Arthur Kavanaugh Iain B. McInnes L. Puig Christopher T. Ritchlin Proton Rahman Alan M. Mendelsohn
Topics: Rheumatoid Arthritis Research and Therapies (21 papers)Autoimmune and Inflammatory Disorders Research (17 papers)Chronic Lymphocytic Leukemia Research (7 papers)
Cited by: Rheumatology Hematology Immunology
Journals: The Lancet Blood The Journal of Infectious Diseases
Partner nations: United States United Kingdom Canada

In The Last Decade

Mittie K. Doyle

41 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

2013 606 citations Iain B. McInnes, Arthur Kavanaugh et al. The Lancet profile →
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

2014 508 citations Christopher T. Ritchlin, Proton Rahman et al. Annals of the Rheumatic Diseases profile →
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

2009 423 citations Josef S Smolen, Jonathan Kay et al. The Lancet profile →

Peers

Countries citing papers authored by Mittie K. Doyle

Since Specialization

Citations

This map shows the geographic impact of Mittie K. Doyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mittie K. Doyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mittie K. Doyle more than expected).

Fields of papers citing papers by Mittie K. Doyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mittie K. Doyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mittie K. Doyle. The network helps show where Mittie K. Doyle may publish in the future.

Co-authorship network of co-authors of Mittie K. Doyle

This figure shows the co-authorship network connecting the top 25 collaborators of Mittie K. Doyle. A scholar is included among the top collaborators of Mittie K. Doyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mittie K. Doyle. Mittie K. Doyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialbreakdown → 2014 ·Annals of the Rheumatic Diseases ·Christopher T. Ritchlin,Proton Rahman,Arthur Kavanaugh,Iain B. McInnes,L. Puig,Shu Li,Yuhua Wang,Yaung‐Kaung Shen,Mittie K. Doyle,Alan M. Mendelsohn,Alice B. Gottlieb,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	508
2	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis 2013 ·Lara D. Veeken ·Daniel E. Fürst,Jonathan Kay,Mary Chester Wasko,Edward Keystone,Arthur Kavanaugh,Atul Deodhar,Frederick T. Murphy,Jeanette H. Magnus,Elizabeth C. Hsia,Benjamin Hsu,Stephen Xu,Mahboob U. Rahman,Mittie K. Doyle	26
3	The Primary Care Physician in the Early Diagnosis of Systemic Sclerosis: The Cornerstone of Recognition and Hope 2013 ·The American Journal of the Medical Sciences ·Lesley Ann Saketkoo,Jeanette H. Magnus,Mittie K. Doyle	16
4	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialbreakdown → 2013 ·The Lancet ·Iain B. McInnes,Arthur Kavanaugh,Alice B. Gottlieb,L. Puig,Proton Rahman,Christopher T. Ritchlin,Carrie Brodmerkel,Shu Li,Yuhua Wang,Alan M. Mendelsohn,Mittie K. Doyle	606
5	Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial 2013 ·Lara D. Veeken ·Mittie K. Doyle,Mahboob U. Rahman,Bart Frederick,C. Birbara,(unknown),Gary Toedter,Xiaoying Wu,Dion Chen,Veena K. Ranganath,Mark Westerman,Daniel E. Fürst	37
6	Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti–tumor necrosis factor antibody, in Phase III clinical trials 2012 ·Arthritis Care & Research ·Elizabeth C. Hsia,John J. Cush,Eric L. Matteson,Anna Beutler,Mittie K. Doyle,Benjamin Hsu,Stephen Xu,Mahboob U. Rahman	48
7	Interferon‐γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti–tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis 2012 ·Arthritis & Rheumatism ·Elizabeth C. Hsia,Neil W. Schluger,John J. Cush,Richard E. Chaisson,Eric L. Matteson,Stephen Xu,Anna Beutler,Mittie K. Doyle,Benjamin Hsu,Mahboob U. Rahman	62
8	Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160 2012 ·Annals of the Rheumatic Diseases ·Josef S Smolen,Jonathan Kay,Robert Landewé,Eric L. Matteson,Norman Gaylis,J. Wollenhaupt,Frederick T. Murphy,Yiying Zhou,Elizabeth C. Hsia,Mittie K. Doyle	49
9	Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years 2011 ·Annals of the Rheumatic Diseases ·Mahboob U. Rahman,Jacqueline Buchanan,Mittie K. Doyle,E. C. Hsia,(unknown),Shreekant Parasuraman,Daniel Aletaha,E. L. Matteson,Philip G. Conaghan,Edward Keystone,D. van der Heijde,Josef S Smolen	61
10	GOLIMUMAB SIGNIFICANTLY IMPROVES PHYSICAL FUNCTION AND FATIGUE IN RA PATIENTS PREVIOUSLY TREATED WITH ANTI-TNF AGENTS: RESULTS FROM THE GO-AFTER STUDY 2010 ·Lara D. Veeken ·(unknown),P Wordsworth,Mittie K. Doyle,J. Smolen,Jacqueline Buchanan,E. L. Matteson,E. C. Hsia,Robert Landewé,(unknown),(unknown),(unknown),(unknown)	3
11	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial 2010 ·Annals of the Rheumatic Diseases ·Marco Matucci‐Cerinic,CP Denton,D.E. Furst,Maureen D. Mayes,Vivien Hsu,Patrick Carpentier,Frederick M. Wigley,C. M. Black,Barri J. Fessler,Peter A. Merkel,Janet Pope,Nadera Sweiss,Mittie K. Doyle,Bernhard Hellmich,Thomas A. Medsger,A. Morganti,Frank Krämer,J H Korn,James R. Seibold	322
12	GOLIMUMAB, A HUMAN TNF-ALPHA mu ONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS PREVIOUSLY TREATED WITH ANTI-TNF-ALPHA AGENTS (GO-AFTER STUDY) 2009 ·Lara D. Veeken ·P Wordsworth,Josef S Smolen,(unknown),Mittie K. Doyle,Robert Landewé,Eric L. Matteson,(unknown),E. C. Hsia,(unknown),(unknown)	1
13	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialbreakdown → 2009 ·The Lancet ·Josef S Smolen,Jonathan Kay,Mittie K. Doyle,Robert Landewé,Eric L. Matteson,J. Wollenhaupt,Norman Gaylis,Frederick T. Murphy,Jeffrey Neal,Yiying Zhou,Sudha Visvanathan,Elizabeth C. Hsia,Mahboob U. Rahman	423
14	Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab 2009 ·Arthritis Care & Research ·Jürgen Braun,Désirée van der Heijde,Mittie K. Doyle,Chenglong Han,Atul Deodhar,Robert D. Inman,Kurt de Vlam,Gerd R Burmester,Filip Van den Bosch,Stephen Xu,Sudha Visvanathan,Mahboob U. Rahman	27
15	Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis 2009 ·Arthritis & Rheumatism ·Paul Emery,Roy Fleischmann,Larry W. Moreland,Elizabeth C. Hsia,Ingrid Strusberg,Patrick Durez,Peter Nash,Eric Amante,Melvin Churchill,Won Park,Bernardo A. Pons‐Estel,Mittie K. Doyle,Sudha Visvanathan,Weichun Xu,Mahboob U. Rahman	335
16	Treatment with Infliximab plus Methotrexate Improves Anemia in Patients with Rheumatoid Arthritis Independent of Improvement in Other Clinical Outcome Measures—A Pooled Analysis from Three Large, Multicenter, Double-Blind, Randomized Clinical Trials 2008 ·Seminars in Arthritis and Rheumatism ·Mittie K. Doyle,Mahboob U. Rahman,Chenglong Han,John Han,Jon T. Giles,Clifton O. Bingham,Joan M. Bathon	48
17	Interferon-Induced Sarcoidosis 2006 ·JCR Journal of Clinical Rheumatology ·Mittie K. Doyle,Ruth Berggren,Jeanette H. Magnus	39
18	Vasculitis associated with connective tissue disorders 2006 ·Current Rheumatology Reports ·Mittie K. Doyle	15
19	Cytokines in Murine Lyme Carditis: Th1 Cytokine Expression Follows Expression of Proinflammatory Cytokines in a Susceptible Mouse Strain 1998 ·The Journal of Infectious Diseases ·Mittie K. Doyle,Sam R. Telford,Lisa G. Criscione,Steven C. Lin,A Spielman,Ellen M. Gravallese	32
20	Heterotopic ossification in the setting of neuromuscular blockade 1997 ·Arthritis & Rheumatism ·(unknown),Peter A. Merkel,Gary S. Perlmutter,Mittie K. Doyle,Stephen M. Krane,(unknown)	18

About Mittie K. Doyle

Mittie K. Doyle is a scholar working on Rheumatology, Hematology and Genetics, having authored 41 papers that have together received 3.1k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (21 papers), Autoimmune and Inflammatory Disorders Research (17 papers) and Chronic Lymphocytic Leukemia Research (7 papers). The work is most often cited by research in Rheumatology (2.0k citations), Hematology (1.2k citations) and Immunology (1.4k citations). Mittie K. Doyle has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Mahboob U. Rahman, Elizabeth C. Hsia, Arthur Kavanaugh, Iain B. McInnes, L. Puig, Christopher T. Ritchlin, Proton Rahman, Alan M. Mendelsohn, Alice B. Gottlieb and Shu Li. Their work appears in journals such as The Lancet, Blood and The Journal of Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact